Population pharmacokinetics and exposure–response of trilaciclib in extensive‐stage small cell lung cancer and triple‐negative breast cancer-Reference-Cited by-同舟云学术

Population pharmacokinetics and exposure–response of trilaciclib in extensive‐stage small cell lung cancer and triple‐negative breast cancer

Published:2022-10-19 Issue:3 Volume:89 Page:1067-1079
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Li Chao¹²,Rich Benjamin³⁴,Bullock Julie M.³,Barrière Olivier³,Marier Jean‐Francois³,Beelen Andrew¹

Affiliation:

1. G1 Therapeutics, Inc. Research Triangle Park North Carolina USA

2. Fosun Pharma USA, Inc. Lexington Massachusetts USA

3. Certara Princeton New Jersey USA

4. InnoMx Montreal Quebec Canada

Funder

G1 Therapeutics

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15549

Reference30 articles.

1. National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer. Version 2.2022.November 2021.

2. National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer. Version 1.2022.November 2021.

3. Antineoplastic Agents and the Associated Myelosuppressive Effects

4. Myeloid toxicity of cancer treatment;Kurtin S;J Adv Pract Oncol,2012

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of trilaciclib, a first-in-class cyclin-dependent kinase 4/6 inhibitor, for the management of metastatic small-cell lung cancer;Medicinal Chemistry Research;2024-07-26

2. Trilaciclib dosage in Chinese patients with extensive-stage small cell lung cancer: a pooled pharmacometrics analysis;Acta Pharmacologica Sinica;2024-05-17

3. Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics;The Journal of Clinical Pharmacology;2024-04-19

4. Use of five-day chronomodulated prescription of palbociclib as myelopreservation drug along with Topotecan in recurrent extensive stage small cell lung carcinoma - A perspective article;International Journal of Molecular and Immuno Oncology;2024-02-19

5. RECENT ADVANCES IN THE DISCOVERY OF CYCLIN-DEPENDENT KINASE 2 (CDK2) SELECTIVE INHIBITORS;Medicinal Chemistry Reviews;2023-11-16